glp-1 agonists vs sglt2 inhibitors Effect of combination treatment with glucagon-like peptide-1 receptor and sodium-glucose cotransporter-2 on incidence of cardiovascular and serious renal events: population based cohort study sglt2 inhibitors and glp-1 receptor

Yanagihara, Y., Shiozawa, K., Takai, M., Kyogoku, M

Puente et al., 2016)

Song DS, Yang JM, Jung YK, Yim HJ, Kim HY, Kim CW, et al

And retatrutide vs tirzepatide comparisons suggest retatrutide edges ahead by 3 to 5 percentage points at comparable dose levels

FDA Warning: RISK OF THYROID C-CELL TUMORS FDA Warning: RISK FOR ILEUS (INTESTINAL BLOCKAGE) (FDA 09/22/2023) References: Buckley ST et al (2018): Transcellular stomach absorption of a derivative glucagon-like peptide-1 receptor agonist

Exposure to pro-oxidant stimuli usually induces Nrf2 activation and upregulation of antioxidant enzyme expression through binding to the antioxidant response element (ARE), localized in the antioxidant enzyme gene promoters